A group of wealthy countries representing 13% of the global population has purchased more than half of the futures dose of future Kovid-19 vaccines, according to an Oxfam report on Wednesday.
The NGO analyzed deals made by pharmaceuticals and vaccine producers for five major vaccine candidates currently in late-stage trials based on data collected by analytics company Airfinity.
Robert Silverman of Oxfam America said, “Access to a life-saving vaccine should not depend on where you live or how much money you have.”
“The development and approval of a safe and effective vaccine is important, but equally important is that vaccines are available and affordable to all. Anywhere the Kovid-19 is the Kovid-19 everywhere.”
Five vaccines Analyzes were conducted from AstraZeneca, Gamalaya / Sputnik, Modern, Pfizer and Synovac.
Oxfam calculated the combined production capacity of these five vaccine candidates at 5.9 billion doses, enough for three billion people to believe that all future vaccines will require or are highly likely to require two doses.
So far 5.3 billion doses have been agreed on supply deals, of which 2.7 billion (51 percent) have been purchased by developed countries, regions and regions including the US, UK, EU, Australia, Hong Kong and Macau, Japan, Switzerland. And Israel.
The remaining 2.6 billion doses have been purchased by other developing countries including India, Bangladesh, China, Brazil, Indonesia and Mexico.
Non-Profit said that one of the key candidates developed by Modern received $ 2.5 billion in taxpayer money, but said it intends to make a profit and has sold options for all its supplies to wealthy countries Have given.
Hence Oxfam and other organizations are making free calls for “people’s vaccines”, which are fairly distributed on a need basis.
“This will only be possible if the Pharmaceutical Corporation allows the vaccine to be widely produced by freely sharing its knowledge with a patent, rather than preserving its monopolys and selling them to the highest bidder,” Oxfam said.
It states that the estimated cost of providing a vaccine for all on Earth was less than one percent of the estimated cost of the global economy Kovid-19.
(Except for the headline, this story has not been edited by NDTV staff and published from a syndicated feed.)